Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC2A1 | P11166 | 1/20 | 0.55 |
| ▸ | CGAS | Q8N884 | 6/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | COMT | P21964 | 1/20 | 0.41 |
| ▸ | PTPN1 | P18031 | 6/20 | 0.41 |
| ▸ | BAG3 | O95817 | 1/20 | 0.39 |
| ▸ | CISD1 | Q9NZ45 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16492058 | 0.83 | SLC2A1 (0.54) | SLC2A1CGASMEN1ALDH1A1LMNA | |
| SCHEMBL16492059 | 0.83 | SLC2A1 (0.57) | SLC2A1CGASMEN1ALDH1A1LMNA | |
| SCHEMBL1613879 | 0.77 | SLC2A1 (0.57) | SLC2A1CGASMEN1ALDH1A1LMNA | |
| SCHEMBL12712427 | 0.74 | SLC2A1 (0.73) | SLC2A1MEN1ALDH1A1LMNAPOLB | |
| SCHEMBL12712445 | 0.74 | SLC2A1 (0.61) | SLC2A1MEN1ALDH1A1LMNAPOLB | |
| SCHEMBL1614974 | 0.71 | SLC2A1 (0.77) | SLC2A1MEN1ALDH1A1LMNAMAPT | |
| SCHEMBL1614379 | 0.71 | SLC2A1 (1.00) | SLC2A1MEN1ALDH1A1LMNAMAPT | |
| SCHEMBL1614903 | 0.71 | SLC2A1 (0.51) | SLC2A1CGASMEN1ALDH1A1LMNA | |
| SCHEMBL2176166 | 0.68 | HSD17B3 (0.61) | SLC2A1CGASMEN1ALDH1A1KMT2A | |
| SCHEMBL2176164 | 0.68 | HSD17B3 (0.61) | SLC2A1CGASMEN1ALDH1A1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9174951-B2 | Glucose transporter inhibitors | OHIO STATE INNOVATION FOUNDATION (US) | 2015-11-03 | — | — | US | disclosed |
| US-20150051255-A1 | GLUCOSE TRANSPORTER INHIBITORS | THE OHIO STATE UNIVERSITY RESEARCH FOUNDATION (US) | 2015-02-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150051255-A1 | GLUCOSE TRANSPORTER INHIBITORS | SLC2A4, SLC2A1, SLC2A2 | SLC2A1 2/4885CGAS 4241/4885MEN1 1875/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.